阿帕他胺治疗晚期前列腺癌32例报道  

Clinical efficacy and safety of apalutamide in the treatment of prostate cancer:case series from West China Hospital

作　　者：叶剑钧 鲍一歌 沈朋飞[1] 刘振华[1] 杨璐[1] 张朋[1] 李响[1] 曾浩[1] 魏强[1] Ye Jianjun;Bao Yige;Shen Pengfei;Liu Zhenhua;Yang Lu;Zhang Peng;Li Xiang;Zeng Hao;Wei Qiang(Department and Institute of Urology,West China Hospital,Sichuan University)

机构地区：[1]四川大学华西医院泌尿外科、泌尿外科研究所,成都610044

出　　处：《微创泌尿外科杂志》2022年第2期76-80,共5页Journal of Minimally Invasive Urology

摘　　要：目的:探讨应用阿帕他胺治疗确诊为晚期前列腺癌的早期疗效及安全性。方法:纳入2021年1月至10月接受阿帕他胺治疗的32例前列腺癌患者,随访6月并记录治疗期间特异性前列腺抗原(PSA)、睾酮水平变化情况,复查全身骨扫描等其他影像学检查,观察并记录药物不良反应。结果:按照PSA工作组(PSA workgroup,PSAWG)标准,32例患者PSA总体缓解率81.3%;mHSPC患者应用阿帕他胺治疗PSA缓解率为100%,nmCRPC患者PSA缓解率为90.9%,mCRPC患者PSA缓解率为58.3%。阿帕他胺总体安全性良好,以皮疹,乏力为主,无Ⅲ级以上不良反应发生。结论:应用阿帕他胺治疗前列腺癌,早期疗效确切,安全性较高,可作为前列腺癌治疗的推荐方案之一。Objective:To analyze the early efficacy and safety of apalutamide treatment for the patients who were diagnosed as prostate cancer,and provide experience for future treatment.Methods:A total of 32 cases of prostate cancer in West China Hospital from January 2021 to October 2021 were treated with apalutamide.The clinical data were recorded and analyzed,including prostate specific antigen(PSA),testosterone level,bone scanning,CT,MRI and adverse events.Results:According to PSA workgroup standard,the PSA response rate of total 32 patients was 81.3%.For the patients at different disease stage,including metastatic hormone sensitive prostate cancer,non metastatic castration resistant prostate cancer and metastatic castration resistant prostate cancer,PSA response rate of these patients was 100%,90.9%and 58.3%,respectively.Generally,apalutamide was well tolerant.Rash and fatigue were common and there was no adverse events at grade 3 or above.Conclusion:Apalutamide showed a great early clinical efficacy and high safety,which should be recommended for treatment of prostate cancer.

关 键 词：前列腺肿瘤 前列腺特异抗原 治疗结果 

分 类 号：R737.25[医药卫生—肿瘤]